News: Regeneus chairman acquires stake with on market buying

Regeneus (ASX:RGS) chairman Dr Roger Aston has acquired shares in the company, acquiring 51,179 shares in an on-market trade.

He paid $0.195 each, or a total of $9979.9, for the shares.

In May, the company received ethics approval to start first-in-human trial of its promising cancer treatment in Sydney.

RGSH4K is produced from a patient’s own cancer cells and combined with a proprietary immunostimulant, to stimulate the immune system.

The trial has its genesis in promising results during canine trials, where the majority of treated dogs outliving the average expected survival time for their particular type of cancer.

It is expected to demonstrate that this personalised treatment is relevant to primary and secondary tumours and will reduce the risk of tumour recurrence.

This also has the potential to target a wide range of hard-to-treat cancers with a single product.

   
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.